Reforgene Medicine was selected into the TOP50 Most Influential Companies in Healthcare in 2024
On May 15, 2025, the "2024 China Medical and Health Industry Investment and Financing Honor List" was officially announced. With its innovative technology research and development capabilities, forward-looking strategic layout and industry-leading practices, Reforgene Medicine has been listed on the "TOP50 Most Influential Companies in Healthcare in 2024" list, demonstrating Reforgene Medicine's comprehensive competitiveness and sustainable development potential in the medical and healthcare field.
This year's selection pays special attention to the company's performance in core technological breakthroughs, global market expansion, and inclusive medical practice. It emphasizes not only the sustainable growth of commercial value, but also the substantial contribution to the construction of the public health system. Reforgene Medicine has demonstrated strong technological innovation capabilities, strong technological subversion, and rapid response to clinical needs. Its development path provides an innovation paradigm that the industry can learn from.
Adding more glory is another evidence that the capital market and industrial institutions are unanimously optimistic about the innovative development of Reforgene Medicine. In the future, as policy support and capital resources continue to increase, Reforgene Medicine is expected to continue to make breakthroughs in technological challenges and model innovation, bring curative solutions to more diseases, and contribute Chinese wisdom to global health.
Annual China Medical and Health Industry Investment and Financing Honor List
The "Annual China Medical and Health Industry Investment and Financing Honor List" is jointly launched by CHC Medical Consulting and CITIC Securities. It focuses on the five core dimensions of technological innovation, capital empowerment, commercialization process, social responsibility and industry collaboration. Through multiple rounds of reviews and cross-validation, it systematically evaluates the value creation capabilities and industry influence of enterprises in the medical and health field. This year's selection covers key tracks such as pharmaceutical research and development, high-end medical devices, digital medicine, and medical services. It aims to discover benchmark companies that promote industrial upgrading and solve clinical needs, and inject new momentum into the development of the industry.
About Reforgene Medicine
Reforgene Medicine is China's leading gene-editing drug innovation company. It is driven by gene-editing technology and is committed to the birth of innovative drugs. Reforgene Medicine is an international high-level team that applied gene editing early to explore the treatment of genetic diseases. It has continued to accumulate pioneering achievements in the fields of hematology, ophthalmology, liver and other diseases. It has a high level of technological accumulation in aspects including gene editing tool innovation, discovery of drug strategies, construction of new animal models, and multi-level drug efficacy and safety assessment. It has two major innovative drug directions, in vivo and in vitro. Reforgene Medicine's mission is to provide accessible and curative medicines to patients with serious diseases based on innovative genetic technologies. Currently, we have pipelines in the fields of genetic diseases, complex diseases and tumors. Among them, innovative drugs for β-thalassaemia have achieved world-leading clinical progress. In α-thalassaemia, we have achieved a breakthrough in curing the world’s first patient. The IND application for the world’s first gene-editing drug for Usher syndrome has been approved by Chinese and American regulatory authorities.
Read 183